The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes

Journal of Virology

Volumn 72, Issue 5, 1998, Pages 4038-4048

  Johnson, Rowena J ^a   Stack, Maria ^a   Hazlewood, Sheila A ^a,c   Jones, Matthew ^a   Blackmore, Colin G ^a,d   Hu, Li Fu ^b   Rowe, Martin ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KEELE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MEMBRANE PROTEIN;

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE DELETION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS MUTATION; VIRUS ONCOGENE;

EID: 0031957012     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.5.4038-4048.1998     Document Type: Article

References (69)

1. Arenzana-Seisdedos, F., B. Fernandez, I. Dominguez, J. M. Jacqué, D. Thomas, M. T. Diaz-Meco, J. Moscat, and J. L. Virelizier. 1993. Phosphatidylcholine hydrolysis activates NF-κB and increases human immunodeficiency virus replication in human monocytes and T lymphocytes. J. Virol. 67:6596-6604.
2. Bachelerie, F., J. Alcami, F. Arenzana-Seisdedos, and J.-L. Virelizler. 1991. HIV enhancer activity perpetuated by NF-κB induction on infection of monocytes. Nature 350:709-712.
3. Baeuerle, P., and D. Baltimore. 1996. NF-κB: ten years after. Cell 87:13-20.
4. Baichwal, V., and B. Sugden. 1989. The multiple membrane-spanning segments of the BNLF-1 oncogene from Epstein-Barr virus are required for transformation. Oncogene 4:67-74.
5. Baichwal, V. R., and B. Sugden. 1988. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461-467.
6. Ben-Bassat, H., N. Goldblum, S. Mitrani, T. Goldblum, J. M. Yoffey, M. M. Cohen, Z. Bentwitch, B. Ramot, E. Klein, and G. Klein. 1977. Establishment in culture of a new type of lymphocyte from a "Burkitt-like" lymphoma (line D.G.-75). Int. J. Cancer 19:27-33.
7. Brattsand, G., D. A. Cantrell, S. Ward, F. Ivars, and M. Gulberg. 1990. Signal transduction through the T-cell receptor-CD3 complex: evidence for heterogeneity in receptor coupling. J. Immunol. 144:3651-3658.
8. Brodeur, S. R., G. Cheng, D. Baltimore, and D. A. Thorley-Lawson. 1997. Localization of the major NF-κB-activating site and the sole TRAF3 binding site of LMP1 defines two distinct signalling motifs. J. Biol. Chem. 272:19777-19784.
9. Chen, M. L., C. N. Tsai, C. L. Liang, C. H. Shu, C. R. Huang, D. Sulitzeanu, S. T. Liu, and Y. S. Chang. 1992. Cloning and characterisation of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131-2140.
10. Chen, W. G., Y. Y. Chen, M. M. Bacchi, C. E. Bacchi, M. Alvarenga, and L. M. Weiss. 1996. Genotyping of Epstein-Barr-Virus in Brazilian Burkitts lymphoma and reactive lymphoid tissue-type A with a high prevalence of deletions within the latent membrane protein gene. Am. J. Pathol. 148:17-23.
11. Contreras-Salazar, B., B. Ehlin-Henriksson, G. Klein, and M. G. Masucci. 1990. Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J. Virol. 64:5441-5447.
12. Dawson, C. W., A. B. Rickinson, and L. S. Young. 1990. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344:777-780.
13. Devergne, O., E. Hatzivassiliou, K. M. Izumi, K. M. Kaye, M. F. Kleijnen, E. Kieff, and G. Mosialos. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol. Cell. Biol. 16:7098-7108.
14. Duckett, C. S., N. D. Perkins, T. F. Kowalik, R. M. Schmid, E.-S. Huang, A. S. Baldwin, Jr., and G. J. Nabel. 1993. Dimerization of NF-κB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an IκB-α (MAD-3). Mol. Cell. Biol. 13:1315-1322.
15. Eliopoulos, A. G., M. Stack, C. W. Dawson, K. M. Kaye, M. Rowe, and L. S. Young. 1997. Epstein Barr virus-encoded LMP1 and CD40 mediate IL6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14:2899-2916.
16. Fåhraeus, R., L.-F. Hu, I. Ernberg, J. Finke, M. Rowe, G. Klein, K. Falk, E. Nilsson, M. Yadav, P. Busson, T. Tursz, and B. Kallin. 1988. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma. Int. J. Cancer 42:329-338.
17. Fåhraeus, R., L. Rymo, J. S. Rhim, and G. Klein. 1990. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345:447-449.
18. Fennewald, S., V. van Santen, and E. Kieff. 1984. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus indicates that it may encode a membrane protein. J. Virol. 51:411-419.
19. Floettmann, J. E., and M. Rowe. 1997. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region-2 (CTAR-2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene 15:1851-1858.
20. Floettman, J. E., et al. Unpublished data.
21. Green, S., I. Issemann, and E. Sheer. 1988. A versatile in vivo and in vitro expression vector for protein engineering. Nucleic Acids Res. 16:369.
22. Grimaldi, J. C., R. Torres, C. A. Kozak, R. Chang, E. A. Clark, M. Howard, and D. A. Cockayne. 1991. Genomic structure and chromosomal mapping of the murine CD40 gene. J. Immunol. 149:3921-3926.
23. Hammarskjöld, M.-L., and M. C. Simurda. 1992. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66:6496-6501.
24. Hayashi, K., W. G. Chen, C. E. Bacci, M. Alvarenga, E. S. Abreau, K. L. Chang, and L. M. Weiss. 1997. Deletion of Epstein-Barr virus latent membrane protein 1 gene in United States and Brazilian Hodgkin's disease and reactive lymphoid tissue: high frequency of a 30-bp deletion. Hum. Pathol. 28:1408-1414.
25. Henderson, S., M. Rowe, C. Gregory, F. Wang, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death. Cell 65: 1107-1115.
26. Herrero, J. A., P. Mathew, and C. V. Paya. 1995. LMP-1 activates NF-κB by targeting the inhibitory molecule IκBa. J. Virol. 69:2168-2174.
27. Hu, L.-F., F. Chen, Q.-F. Zhen, Y.-W. Zhang, Y. Luo, X. Zheng, G. Winberg, I. Ernberg, and G. Klein. 1995. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur. J. Cancer 31A:658-660.
28. Hu, L.-F., F. Chen, X. Zheng, I. Ernberg, S.-L. Cao, B. Christensson, G. Klein, and G. Winberg. 1993. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8:1575-1583.
29. Hu, L.-F., E. R. Zabarovsky, F. Chen, S.-L. Cao, I. Ernberg, G. Klein, and G. Winberg. 1991. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 72:2399-2409.
30. Huen, D. S., S. A. Henderson, D. Croom-Carter, and M. Rowe. 1995. The Epstein-Barr-virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via 2 effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560.
31. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 94:1447-1452.
32. Jones, M. D., L. Foster, T. Sheedy, and B. E. Griffin. 1984. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain of the virus. EMBO J. 3:813-821.
33. Kaye, K. M., O. Devergne, J. N. Harada, K. M. Izumi, R. Yalamanchilli, E. Kieff, and G. Mosialos. 1996. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc. Natl. Acad. Sci. USA 93: 11085-11090.
34. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
35. Khanim, F., Q.-Y. Yao, G. Niedobitek, S. Sihota, A. B. Rickinson, and L. S. Young. 1996. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus associated tumors from different geographic locations. Blood 88:3491-3501.
36. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2396. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
37. Kieser, A., E. Kilger, O. Giles, M. Ueffing, W. Kolch, and W. HammerSchmidt. 1997. AP-1 induction by Epstein-Barr virus latent membrane protein-1 via the SEK/JNK cascade. EMBO J. 16:6478-6485.
38. Kingma, D. W., W. B. Weiss, E. S. Jaffe, S. Kumar, K. Frekko, and M. Raffeld. 1996. Epstein-Barr virus latent membrane protein-1 oncogene deletions - correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood. 88:242-251.
39. Knecht, H., E. Bachmann, P. Brousset, S. Rothenberger, H. Einsele, V. S. Lestou, G. Delsol, F. Bachmann, P. F. Ambros, and B. F. Odermatt. 1995. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10:523-528.
40. Knecht, H., E. Bachmann, P. Brousset, K. Sandvej, D. Nadal, F. Bachmann, B. F. Odermatt, G. Delsol, and G. Pallesen. 1993. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkins disease and are identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942.
41. Knecht, H., M. Raphael, C. McQuain, S. Rothenberger, G. Pihan, S. Camilleri-Broet, E. Bachmann, G. Kersbaw, S. Ryan, E. Kittler, P. Quesenberry, D. Schlaifer, B. Woda, and P. Brousset. 1996. Deletion variants within the NF-κB activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood 87:876-881.
42. Laherty, C. D., H. M. Hu, A. W. Opipari, F. Wang, and V. M. Dixit. 1992. Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J. Biol. Chem. 267:24157-24160.
43. Li, S.-N., Y.-S. Chang, and S.-H. Liu. 1996. Effect of a 10-amino-acid deletion on the oncogenic activity of latent membrane 1 of Epstein-Barr virus. Oncogene 12:2129-2135.
44. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol. 55:710-720.
45. Miller, W. E., H. S. Earp, and N. Raab Traub. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69:4390-4398.
46. Miller, W. E., R. H. Edwards, D. M. Walling, and N. Raab-Traub. 1994. Sequence variation in the Epstein-Barr virus latent membrane protein-1. J. Gen. Virol. 75:2729-2740.
47. Miller, W. E., G. Mosialos, E. Kief, and N. Raab-Traub. 1996. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J. Virol. 71:586-594.
48. Mitchell, T., and B. Sugden. 1995. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 69:2968-2976.
49. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J. Virol. 67:1638-1646.
50. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. Biochemical, genetic, and functional analyses of the phospnorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J. Virol. 67:2637-2645.
51. Mosialos, G., M. Birkenbach, R. Yalamanchili, T. VanArsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell 80: 389-399.
52. Nicholson, L. J., P. Hopwood, I. Johannessen, J. R. Salisbury, J. Codd, D. Thorley-Lawson, and D. H. Crawford. 1997. Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene 15:275-283.
53. Peng, M., and E. Lundgren. 1993. Transient expression of the Epstein Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell type independent induction of CD23, CD21 and ICAM-1. Leukemia 7:104-112.
54. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
55. Rowe, M., H. S. Evans, L. S. Young, K. Hennessy, E. Kieff, and A. B. Rickinson. 1987. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68:1575-1586.
56. Rowe, M., M. Peng-Pilon, D. S. Huen, R. Hardy, D. Croom-Carter, E. Lundgren, and A. B. Rickinson. 1994. Up-regulation of Bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-speciflc response that is delayed relative to NF-κB activation and to induction of cell surface markers. J. Virol. 68:5602-5612.
57. Rowe, M., D. T. Rowe, C. D. Gregory, L. S. Young, P. J. Farrell, H. Rupani, and A. B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J. 6:2743-2751.
58. Sample, J., E. F. Kieff, and E. D. Kieff. 1994. Epstein-Barr virus type-1 and rype-2 have nearly identical LMP-1 transforming genes. J. Gen. Virol. 75: 2741-2746.
59. Sandberg, M., W. Hammerschmidt, and B. Sugden. 1997. Characterization of LMP1 association with TRAF1, TRAF2, and TRAF3. J. Virol. 71:4649-4656.
60. Sandvej, K., M. Munch, and S. Hamilton-Dutoit. 1996. Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice. J. Clin. Pathol. 49:M290-M297.
61. Sandvej, K., S. C. Peh, B. S. Andresen, and G. Pallesen. 1994. Identification of potential hotspots in the carboxy terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30bp deletion in Malaysian and Danish T-cell lymphomas. Blood 84:4053-4060.
62. Scheinfeld, A. G., R. G. Nador, E. Cesarman, A. Chadburn, and D. M. Knowles. 1997. Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am. J. Pathol. 151:805-812.
63. Voraberger, G., R. Schäfer, and C. Stratowa. 1991. Cloning of the human gene for intracellular adhesion molecule 1 and analysis of its 5′-regulatory region. Induction by cytokines and phorbol ester. J. Immunol. 147:2777-2786.
64. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
65. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:4173-4184.
66. Wang, F., C. D. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. B. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309-2318.
67. Wang, S., M. Rowe, and E. Lundgren. 1996. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B cell lines. Cancer Res. 56:4610-4613.
68. Young, L., C. Dawson, D. Clark, H. Rupani, P. Busson, T. Tursz, A. Johnson, and A. Rickinson. 1988. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69:1051-1065.
69. Zheng, N., F. Yuan, L. Hu, F. Chen, G. Klein, and B. Christensson. 1994. Effect of a B-lymphocyte and NPC derived EBV-LMP1 gene expression on in vitro growth and differentiation of human epithelial cells. Int. J. Cancer 57:747-753.